Mabwell Advances SST001 PET Tracer to Phase I Trial
SHANGHAI, CHINA, April 14, 2026 Mabwell (688062.SH) has announced that SST001 (18F-FD4), an innovative α-synuclein-targeted PET tracer developed by...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
SHANGHAI, CHINA, April 14, 2026 Mabwell (688062.SH) has announced that SST001 (18F-FD4), an innovative α-synuclein-targeted PET tracer developed by...
